This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

This Is Why Humira Isn't AbbVie's Biggest Problem Right Now

Source: 
Motley Fool
snippet: 

Despite launching nearly two decades ago, worldwide sales of AbbVie's (NYSE:ABBV) lead drug, Humira still generates more revenue than most countries. As you can imagine, patent-protected exclusivity expected to expire in the U.S. in 2023 has been a major concern for AbbVie for a long time. In fact, eight years ago, Abbott spun out its biopharmaceutical segment into a separate company to protect the parent from Humira's impending patent cliff.